Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

CLABI1B:LX

539.19 USD 2.93 0.55%

As of 00:59:30 ET on 04/16/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (CLABI1B)

Year To Date: +20.47% 3-Month: +13.61% 3-Year: +46.08% 52-Week Range: 319.73 - 548.43
1-Month: +1.45% 1-Year: +67.02% 5-Year: +30.13% Beta vs NBI: 1.03

Mutual Fund Chart for CLABI1B

No chart data available.
  • CLABI1B:LX 539.19
  • 1M
  • 1Y
Interactive CLABI1B Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for CLABI1B

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: 10-05-2001 Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for CLABI1B

NAV (on 2015-04-16) 539.19
Assets (M) (on 2015-04-16) 259.99
Fund Leveraged N
Minimum Investment 1,000,000.00
Minimum Subsequent Investment 250,000.00

Dividends for CLABI1B

No dividends reported

Fees & Expenses for CLABI1B

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 1.20
Redemption Fee 0.00
12b1 Fee -
Expense Ratio -

Top Fund Holdings for CLABI1B

Filing Date: 01/30/2015
Name Position Value % of Total
Biogen Inc 46,745 18,191,284 7.691%
Celgene Corp 150,276 17,906,888 7.571%
Gilead Sciences Inc 162,484 17,033,198 7.202%
Amgen Inc 105,973 16,135,449 6.822%
Incyte Corp 145,000 11,557,950 4.887%
Regeneron Pharmaceuticals Inc 27,000 11,249,820 4.757%
BioMarin Pharmaceutical Inc 115,444 11,216,539 4.742%
Vertex Pharmaceuticals Inc 90,000 9,912,600 4.191%
Alexion Pharmaceuticals Inc 52,752 9,666,276 4.087%
Medivation Inc 80,000 8,705,600 3.681%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil